ArticleFrontiers in neurology2024
A population-based analysis of the global burden of epilepsy across all age groups (1990-2021): utilizing the Global Burden of Disease 2021 data.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative effectiveness of non-pharmacological interventions on anxiety, depression, and quality of life in patients with epilepsy: a systematic review and network meta-analysis.Frontiers in psychiatry · 2025Pooled it
- An Investigation of the Relationship Between Social Support, Psychological Resilience, and Post-Traumatic Growth in Patients With Epilepsy.Brain and behavior · 2026Article
- Mindfulness meditation increases interictal epileptiform discharges in meditation-naïve surgical epilepsy patients.Epilepsia · 2026Article
- Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990-2021).Neuroprotection (Chichester, England) · 2026Review
- Comparative trends in idiopathic epilepsy burden in China and worldwide based on Global Burden of Disease Study 2021.Epilepsy & behavior reports · 2026Article
- Bayesian age-period-cohort analysis and trend prediction of epilepsy disease burden in China, 1990-2021.Epileptic disorders : international epilepsy journal with videotape · 2026Article
- Review
- Treatment patterns and adverse events of antiseizure medications among adult patients with epilepsy: a single centre observational cross-sectional study in Northern Sri Lanka.BMC neurology · 2026Observational
- Factors associated with epileptiform discharges in patients visiting a memory clinic: A retrospective study.Epilepsy & behavior reports · 2026Article
- Hemispherotomy for Drug-Resistant Epilepsy in a Low-Resource Setting: Surgical Outcomes and Quality of Life in 23 Children Treated in a Hybrid Program in Panama.Pediatric neurosurgery · 2026Article
- The translocator protein antagonist ONO-2952 attenuates neuroinflammation and neuronal apoptosis in an epilepsy rat model.Frontiers in neurology · 2026Article
- Global, regional, and national children and adolescent epilepsy burden, 1990-2021: an analysis based on the global burden of disease study 2021.Annals of medicine · 2025Article
- Global, regional, and national burden and trends of idiopathic epilepsy among children and adolescents from 1990 to 2021: insights from the global burden of disease study 2021.Annals of medicine · 2025Article
- Global burden trends of idiopathic epilepsy in young adults from 1990 to 2035: based on the global burden of disease study 2021.BMC neurology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the trends in epilepsy prevalence, incidence, mortality, and disability-adjusted life-years (DALYs) in all ages, with risk factors for epilepsy - associated death, from 1990 to 2021. Methods: Using the standardized Global Burden of Disease (GBD) methodologies, we evaluated the burden of epilepsy in 204 countries and regions from 1990 to 2021, aiming to derive a more precise representation of the health burden posed by epilepsy by considering four distinct types of epidemiological data, namely the prevalence, incidence, mortality, and DALYs. The presented data were meticulously estimated and displayed both as numerical counts and as age-standardized rates per 100,000 persons of the population. All estimates were calculated with 95% uncertainty intervals (UI). Finding: In 2021, there were 24,220,856 (95% UI: 18,476,943-30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71-389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24-53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46-1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66-225.90); 154.25 per 100,000 population for females [114.73-201.76], and 201.29 per 100,000 population for males [157.93-252.74]. All of the ASPR, ASIR, ASMR and ASDR of males were higher than those of females, and the ASIR of epilepsy was the highest in children aged 0-14, at 61.00(95% UI: 39.09-86.21), while the older adult group aged 70+ has the highest ASMR of 5.67(95% UI: 4.76-6.18). From 1990 to 2021, the number of epilepsy-related deaths and DALYs both decreased. However, the ASPR of epilepsy increased by about 6.9% (95% UI: -0.10-0.26), and the ASIR increased by almost 12% (95% UI: 0.05-0.33). The trends in ASPR, ASIR, ASMR and ASDR exhibited notable variations across different regions. Conclusion: Epilepsy is an increasing global health challenge with rising prevalence and incidence. Results of this cross-sectional study suggest that despite the global decline in deaths and DALYs, Epilepsy remains an important cause of disability and death, especially in low SDI regions. An improved understanding of the epidemiology of epilepsy may potentially have considerable benefits in reducing the global burden of epilepsy, by aiding in policy-making in low-income countries, provide data support for research on epilepsy medications and treatment methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.